DexCom, Inc. Class Action Lawsuit - DXCM

The filed complaint alleges that DexCom, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) DexCom had made material design changes to The Company’s glucose monitoring products, the G6 and G7, unauthorized by the U.S. Food and Drug Administration; (ii) the foregoing design changes rendered the G6 and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, defendants’ purported enhancements to the G7, as well as the device’s reliability, accuracy, and functionality, were overstated; (iv) defendants downplayed the true scope and severity of the issues and health risks posed by adulterated G7 devices; (v) all the foregoing subjected DexCom to an increased risk of heightened regulatory scrutiny and enforcement action, as well as significant legal, reputational, and financial harm; and (vi) as a result, defendants’ public statements were materially false and/or misleading at all relevant times.

In order to be eligible to join the DXCM class action lawsuit, you must have incurred a loss on shares of DexCom purchased during the class period listed above.

If you suffered a loss in DexCom during the relevant time frame or pursuant to the relevant offering(s), you have until December 26, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.